OOIR: Observatory of International Research

Papers

(The H4-Index of Biomarker Research is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion	175
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	165
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	157
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	146
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	134
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	129
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	122
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	110
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	97
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	92
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	86
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	86
Mitochondrial transfer in hematological malignancies	85
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	83
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	81
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	81
p53 biology and reactivation for improved therapy in MDS and AML	78
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	77
Unveiling the potential of CLL-1: a promising target for AML therapy	76
Donor T cells for CAR T cell therapy	72
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	71
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	71
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	68
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	68
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	68

Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	67
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	67
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	66
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	66
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	65
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	63
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	63
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	61
Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis	59
The role of BATF in immune cell differentiation and autoimmune diseases	59
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	58
Targeting interleukin-1β and inflammation in lung cancer	57
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	57
The role and metabolic adaptations of neutrophils in premetastatic niches	56
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	54
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	54
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	52
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	51
Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia/lymphoma	48
The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications	48
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	48
BRD4: an effective target for organ fibrosis	46
Glycochenodeoxycholic acid promotes hepatocarcinogenesis by inducing hepatic progenitor cell differentiation into cancer-associated fibroblasts via sphingosine-1-phosphate receptor 2 signalling	46